Australia markets closed

AXSM Jun 2024 90.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
16.500.00 (0.00%)
As of 09:57AM EDT. Market open.
Full screen
Previous close16.50
Open16.50
Bid20.40
Ask23.60
Strike90.00
Expiry date2024-06-21
Day's range16.50 - 16.50
Contract rangeN/A
Volume19
Open interest40
  • GlobeNewswire

    Axsome Therapeutics to Participate in Upcoming Investor Conferences

    NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Axsome will participate in two upcoming investor conferences. The conference details are as follows: William Blair 44th Annual Growth Stock Conference, on Wednesday, June 5, at 2 p.m. Central Time. Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will pre

  • GlobeNewswire

    Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024

    Data on solriamfetol featured in two oral plenary sessionsNEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced five presentations, including two featured oral plenary presentations, on solriamfetol at SLEEP 2024, the 38th annual meeting of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SR

  • GlobeNewswire

    Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting

    NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that data from its industry-leading portfolio of novel products for CNS disorders will be presented at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, being held May 28-31, 2024, in Miami Beach, Florida. The presentations include new d